



## Investor Relations

### News Release

[<< Back](#)

[Home](#)

[Stock quote](#)

[Board of Directors](#)

[Press Releases](#)

[Financial Reports](#)

[CEO Filings](#)

[Analyst coverage](#)

[Events](#)

[Info Request form](#)

[Email alerts](#)

#### Hi-Tech Pharmacal's ECR Subsidiary to Launch a New Dermatitis Treatment

AMITYVILLE, N.Y., Jan 07, 2010 (BUSINESS WIRE) -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that it received clearance from the FDA to market Tropazone(TM) lotion, a prescription dermatological product which will be promoted by Hi-Tech's branded marketing subsidiary, ECR Pharmaceuticals Co., Inc. The product is indicated for the treatment of various dermatological conditions including atopic dermatitis, allergic contact dermatitis, and radiation dermatitis. Tropazone(TM) utilizes patented Lyphazome(TM) technology. This delivery system prolongs product activity while enhancing penetration and hydration of the skin. Tropazone(TM) is patent protected, and two additional patents are pending. Tropazone(TM) will be promoted by ECR's 55 person field force beginning February 2010.

"We are pleased to introduce another unique prescription branded product to the market", said David Seltzer, President and CEO of Hi-Tech Pharmacal. "Tropazone(TM) lotion provides physicians and their patients with an effective delivery system to treat dermatitis."

Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded prescription and OTC products. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company's Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace. Hi-Tech's ECR Pharmaceuticals subsidiary markets branded prescription products.

Forward-looking statements (statements which are not historical facts) in this Press Release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, the regulatory environment, including without limitation, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results and other results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward looking statements which speak only as of the date made. Hi-Tech is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Hi-Tech Pharmacal Co., Inc.

Hi-Tech Pharmacal Co., Inc.  
Bill Peters, 631-789-8228

[ [Home](#) ] [ [Welcome to Hi-Tech](#) ] [ [Products](#) ] [ [Investor Relations](#) ] [ [Subsidiaries](#) ] [ [Contact Info](#) ]

©2001 Hi-Tech Pharmacal Co., Inc. (a NASDAQ company)  
369 Bayview Avenue, Amityville, New York 11701  
Phone: 631.789.8228 Fax: 631.789.8429